# Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast Cancer

> **NCT07590505** · PHASE3 · COMPLETED · sponsor: **Cancer Research Antwerp** · enrollment: 132 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Standard of Care (SOC) - Normofractionated Sequential Boost Radiation Therapy
- **RADIATION:** Experimental - UltraHypofractionated Sequential Boost Radiation Therapy

## Key facts

- **NCT ID:** NCT07590505
- **Lead sponsor:** Cancer Research Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-29
- **Primary completion:** 2025-11-28
- **Final completion:** 2026-03-25
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07590505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07590505, "Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07590505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*